NasdaqGS:MPLTBiotechs
Does MapLight Therapeutics’ (MPLT) Dual Symptom And Cognitive Data Hint At A Differentiated Schizophrenia Strategy?
MapLight Therapeutics recently reported positive topline results from its Phase 2 ZEPHYR trial, where ML-007C-MA met the primary endpoint by delivering a statistically significant and clinically meaningful reduction in schizophrenia symptoms versus placebo, alongside a generally well-tolerated safety profile.
A particularly interesting finding was a robust, independent cognitive benefit in cognitively impaired participants, suggesting ML-007C-MA may affect both psychotic symptoms and...